Leading AI-powered illness diagnosis and care coordination company Viz.ai has announced the extension of their lung disease software. By extracting clinical insights from electronic health records (EHR), Viz.ai hopes to expedite therapy for patients with lung illness by integrating cutting-edge natural language processing (NLP) with their current AI imaging technology. The company's AI-powered platform will be improved by this integration, which could speed up patient identification, shorten treatment times, and maybe improve outcomes for people with lung conditions including lung cancer, asthma, and chronic obstructive pulmonary disease (COPD).
Chronic respiratory disorders are the third biggest cause of mortality worldwide, and lung disease is one of the main causes of sickness and death. By enhancing patient follow-up and care coordination, Viz.ai's platform aims to close important gaps in the diagnosis and treatment of lung disorders. Viz.ai aims to enhance early identification and maximize therapy for high-risk patients by collaborating with research facilities and patient advocacy organizations, including a recent collaboration with the Addario Lung Cancer Medical Institute. More than 1,700 hospitals in the United States and Europe have already implemented the company's AI-driven solutions, which use smart, real-time decision-making tools to enhance patient outcomes and expedite treatment paths.
